Assays for COVID-19 Drug Discovery

Accelerate COVID-19 Drug Discovery and Development Programs Targeting Proinflammatory Cytokines & Others with Qualified Assays

The World Health Organization (WHO) declared COVID-19 as a pandemic in 2020. Although COVID-19 cases have significantly declined since then, medical science experts project the disease and its aftermath will continue as long as the virus continues to spread and mutate – and will continue to pose a danger to human health.

After years of intense study the disease is now better understood, as is its transmission when the SARS-CoV-2 virus infects the respiratory tract and, in severe cases, leads to acute respiratory distress syndrome (ARDS). The high mortality rate in COVID-19 patients has been linked to cytokine release syndrome (CRS), commonly referred to as cytokine storm, which is an excessive and dysregulated production of proinflammatory cytokines by the body’s immune system. Currently, active clinical programs are implemented that focus on developing and repurposing therapeutic drugs for treatment of COVID-19.

Implement Eurofins DiscoverX® cell-based assays to accelerate your COVID-19 drug discovery from basic research through QC lot release programs, particularly in managing proinflammatory cytokines associated with high mortality rate in COVID-19 patients.

Product Highlights
  • Target Specific – Mechanism-of-action (MOA)-based, functional assays for drugs targeting proinflammatory cytokines such as IL-1, IL-6, IL-7, GM-CSF, and TNFα that are implicated in COVID-19 pathology
  • Qualified Bioassays – Accelerate your drug release program into QC lot release with bioassays qualified using approved therapeutics like Actemra® (tocilizumab), Kineret® (anakinra), Leukine® (sargramostim), and Humira® (adalimumab)
  • Complete Understanding – Evaluate both receptor-proximal and -distal responses for a comprehensive understanding of the biologic and small molecule therapeutics MOA
  • Complete Solutions – Utilize Eurofins DiscoverX’s Custom Capabilities for the creation of other COVID-19-relevant receptor assays such as ACE2, TMPRSS2, and more

* Actemra is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group; Kineret is a registered trademark, licensed by Swedish Orphan Biovitrum AB and marketed by Sobi, Inc.; Leukine is a registered trademark licensed to Genzyme Corporation; and Humira is a registered trademark AbbVie, Inc.

VIEW VIDEO

Products

Eurofins DiscoverX offers a variety of cell-based assays for COVID-19 drug discovery and development programs. Contact custom assay development for additional assays or visit Eurofins Discovery to learn more about cell-based and phenotypic assay services.
 

Cell-Based Assays for COVID-19 Drug Discovery

Therapeutic Type or MOA TherapeuticTarget Recommended Cell-Based Assay
Monoclonal antibodies; to be used in combination with protease inhibitors Adalimumab TNFα PathHunter® Adalimumab Bioassay Kit
Combination studies Adalimumab + Tocilizumab TNFα + IL-6 PathHunter Adalimumab Bioassay Kit
PathHunter Tocilizumab Bioassay Kit
Varies Anakira IL-1β PathHunter Anakinra Bioassay Kit
Varies Angiotensin Converting Enzyme (ACE) inhibitors ACE2 Contact Custom Assay Development (Request Early Access)
Varies Angiotensin receptor blockers AGTR1 PathHunter AGTR1 Bioassay Kit
Monoclonal antibodies; to be used in combination with protease inhibitors Camrelizumab PD-1 PathHunter PD-1 Signaling Bioassay Kit
PathHunter PD-1 Cell Lines
Monoclonal antibodies; to be used in combination with protease inhibitors Eculizumab C5AR1 PathHunter C5AR1 Bioassay Kit
C5AR1 Cell Lines
Nonspecific anti-inflammatory and immunisuppressive drugs Fingolimod S1P1; EDG1 Sphingosine 1-phosphate receptor 1 (S1P1; EDG1) Cell Lines
Nonspecific anti-inflammatory and immunosuppressive drugs Fingolimod S1P2; EDG5 Sphingosine 1-phosphate receptor 2 (S1P2; EDG5) Cell Lines
Nonspecifc anti-inflammatory and immunosuppressive drugs Fingolimod S1P3; EDG3 Sphingosine 1-phosphate receptor 3 (S1P3; EDG3) Cell Lines
Nonspecific anti-inflammatory and immunosuppressive drugs Fingolimod S1P4; EDG6 Sphingosine 1-phosphate receptor 4 (S1P4; EDG6) Cell Lines
Antiviral drugs, non-specific Interleukin-2 IL-2 PathHunter IL-2 Dimerization Bioassay Kits
PathHunter IL-2 Dimerization Cell Lines
Kinase inhibitors Jakotinib hydrochloride STAT3 STAT3 Cell Lines
Nonspecifc anti-inflammatory and immunosuppresive drugs Leflunomide Contact Custom Assay Development (Request Early Access)
Monoclonal antibodies; to be used in combination with protease inhibitors Meplazumab Contact Custom Assay Development (Request Early Access)
Monoclonal antibodies; to be used in combination with protease inhibitors PD-1 mAb PD-1 PathHunter PD-1 Signaling Bioassay Kit
PathHunter PD-1 Cell Lines
Miscellaneous others Pirfenidone TGFBR1
PDGFRa
PDGFRb		 PathHunter PDGFRa & PDGFRb Bioassay Kits
PathHunter TGFBR1/TGFBR2 Dimerization Cell Lines
PathHunter PDGFRa & PDGFRb Functional Assay (Cell Lines)
Miscellaneous others rhGM-CSF GM-CSF PathHunter Sargramostim Bioassay Kit
Kinase inhibitors Ruxolitinib STAT3 STAT3 Cell Lines
Nonspecific anti-inflammatory and immunosuppressive drugs Thalidomide Varies SPRINTer™ Protein Turnover Biosensor Platform Contact Custom Assay Development (Request Early Access)
Monoclonal antibodies; to be used in combination with protease inhibitors Tocilizumab IL-6 PathHunter Tocilizumab Bioassay Kit

Additional cell lines and kits (and alternative sizes) are available for the therapeutics indicated above. Please contact technical support for more information.